Immune checkpoint inhibitors, drugs that can help make the immune system recognize and destroy cancer more aggressively, are one of the most important medicines in
SAN FRANCISCO — On the first day of the J.P Morgan Healthcare Conference, a small crowd of demonstrators gathered on a corner of Union Square
SAN FRANCISCO — Over the last three years that Meena Seshamani has led the Center for Medicare, the service has seen sweeping change — much
The standard option for many patients with non-small cell lung cancer today is AstraZeneca’s targeted therapy Tagrisso. A year and a half ago, data showed
Blood stem cell transplants have been central players in treating blood cancers for decades. These procedures can improve patients’ chances of survival and can even
SAN DIEGO — Brian Koffman found himself in a situation a couple years ago that most chronic lymphocytic leukemia patients eventually do: relapse. The expectation
New data suggests researchers may have found one of their most promising candidates yet for the next generation in immunotherapy drugs — bispecific antibodies targeting
SAN DIEGO — Mantle cell lymphoma patients who go into deep remission from a first therapy may not get any benefit from a follow-up transplant
SAN DIEGO — It’s been decades since Vincent Rajkumar, a multiple myeloma physician and researcher at the Mayo Clinic, remembers first feeling that he was
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other